WallStSmart

GE HealthCare Technologies Inc. (GEHC)vsCatheter Precision Inc. (VTAK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 3437400% more annual revenue ($20.63B vs $600,000). GEHC leads profitability with a 10.1% profit margin vs 0.0%. VTAK trades at a lower P/E of 0.1x. GEHC earns a higher WallStSmart Score of 60/100 (C+).

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34

VTAK

Hold

38

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 8.3Quality: 5.0
Piotroski: 4/9Altman Z: -15.82
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued
VTAKUndervalued (+99.2%)

Margin of Safety

+99.2%

Fair Value

$228.68

Current Price

$1.20

$227.48 discount

UndervaluedFair: $228.68Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

VTAK3 strengths · Avg: 10.0/10
P/E RatioValuation
0.1x10/10

Attractively priced relative to earnings

Price/BookValuation
0.2x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
128.0%10/10

Revenue surging 128.0% year-over-year

Areas to Watch

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

VTAK4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$3.05M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-1.8%2/10

ROE of -1.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bull Case : VTAK

The strongest argument for VTAK centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 128.0% demonstrates continued momentum.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Bear Case : VTAK

The primary concerns for VTAK are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

GEHC profiles as a value stock while VTAK is a hypergrowth play — different risk/reward profiles.

GEHC carries more volatility with a beta of 1.18 — expect wider price swings.

VTAK is growing revenue faster at 128.0% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (60/100 vs 38/100). VTAK offers better value entry with a 99.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Catheter Precision Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company is headquartered in Fort Mill, South Carolina.

Visit Website →

Want to dig deeper into these stocks?